Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$29.73
+2.0%
$39.88
$11.20
$72.98
$6.60B1.3714.31 million shs19.78 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$825.42
+0.4%
$844.31
$711.40
$972.53
$782.64B0.343.31 million shs3.67 million shs
MSCI Inc. stock logo
MSCI
MSCI
$565.66
+1.3%
$578.82
$439.95
$642.45
$43.92B1.19554,872 shs569,419 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
0.00%-16.29%-35.60%+15.63%+88.14%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%-2.28%-10.88%+6.00%+5.44%
MSCI Inc. stock logo
MSCI
MSCI
0.00%-0.88%-5.44%-6.94%-0.43%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
3.7592 of 5 stars
4.12.00.00.02.13.31.9
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8003 of 5 stars
2.45.03.34.03.42.51.9
MSCI Inc. stock logo
MSCI
MSCI
4.5922 of 5 stars
2.43.04.23.33.43.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.27
Hold$37.3125.51% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.85
Moderate Buy$1,009.7222.33% Upside
MSCI Inc. stock logo
MSCI
MSCI
2.79
Moderate Buy$649.2314.77% Upside

Current Analyst Ratings Breakdown

Latest MSCI, LLY, and HIMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/18/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$21.00 ➝ $22.00
3/6/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$1,146.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderperform ➝ Underperform$21.00 ➝ $21.00
3/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell ➝ Sell$27.00 ➝ $27.00
3/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$970.00 ➝ $1,100.00
2/26/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$24.00 ➝ $39.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$24.00 ➝ $40.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $35.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$25.00 ➝ $27.00
2/25/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$31.00 ➝ $61.00
2/20/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetUnderperform ➝ Underperform$18.00 ➝ $21.00
(Data available from 3/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.48B4.47N/AN/A$1.61 per share18.46
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$45.04B17.38$13.46 per share61.34$15.05 per share54.85
MSCI Inc. stock logo
MSCI
MSCI
$2.86B15.38$17.74 per share31.89($12.10) per share-46.75
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.5467.5657.16N/A8.19%10.97%8.29%5/5/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$11.7170.4926.521.4023.51%85.24%16.19%5/1/2025 (Estimated)
MSCI Inc. stock logo
MSCI
MSCI
$1.11B$14.0640.2329.712.6138.83%-156.08%22.03%4/22/2025 (Estimated)

Latest MSCI, LLY, and HIMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/22/2025N/A
MSCI Inc. stock logo
MSCI
MSCI
$3.88N/AN/AN/A$746.45 millionN/A
2/24/2025Q4 2024
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.09$0.11+$0.02$0.11$494.56 million$481.14 million
2/6/2025Q4 2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.45$5.32-$0.13$4.88$13.42 billionN/A
1/29/2025Q4 2024
MSCI Inc. stock logo
MSCI
MSCI
$3.96$4.18+$0.22$3.90$747.63 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%+15.21%51.24%11 Years
MSCI Inc. stock logo
MSCI
MSCI
$7.201.27%+20.70%51.21%11 Years

Latest MSCI, LLY, and HIMS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/28/2025
MSCI Inc. stock logo
MSCI
MSCI
quarterly$1.801.1%2/14/20252/14/20252/28/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
MSCI Inc. stock logo
MSCI
MSCI
N/A
0.85
0.85

Institutional Ownership

CompanyInstitutional Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
MSCI Inc. stock logo
MSCI
MSCI
89.97%

Insider Ownership

CompanyInsider Ownership
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
17.71%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%
MSCI Inc. stock logo
MSCI
MSCI
3.31%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
650222.17 million179.79 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000948.17 million948.08 millionOptionable
MSCI Inc. stock logo
MSCI
MSCI
4,76077.65 million75.17 millionOptionable

Recent News About These Companies

Top ETF Stories of Q1 2025
John Hancock Seaport Long/Short Fund Q4 2024 Commentary
John Hancock International Growth Fund Q4 2024 Commentary
MSCI Inc. stock logo
Allianz SE Takes Position in MSCI Inc. (NYSE:MSCI)
Hartford Conservative Allocation Fund Q4 2024 Commentary
Hartford Growth Allocation Fund Q4 2024 Commentary
Hartford Global Impact Fund Q4 2024 Commentary
Hartford International Growth Fund Q4 2024 Commentary
South Korea short-selling resumption set to entice global funds

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$29.72 +0.59 (+2.01%)
Closing price 03:59 PM Eastern
Extended Trading
$29.42 -0.30 (-1.01%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$825.42 +2.91 (+0.35%)
Closing price 03:59 PM Eastern
Extended Trading
$825.15 -0.27 (-0.03%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

MSCI stock logo

MSCI NYSE:MSCI

$565.66 +7.19 (+1.29%)
Closing price 03:59 PM Eastern
Extended Trading
$598.00 +32.34 (+5.72%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MSCI Inc., together with its subsidiaries, provides critical decision support tools and solutions for the investment community to manage investment processes worldwide. The Index segment provides indexes for use in various areas of the investment process, including indexed financial product, such as ETFs, mutual funds, annuities, futures, options, structured products, and over-the-counter derivatives; performance benchmarking; portfolio construction and rebalancing; and asset allocation, as well as licenses GICS and GICS Direct. The Analytics segment offers risk management, performance attribution and portfolio management content, application, an integrated view of risk and return service, and an analysis of market, credit, liquidity, counterparty, and climate risk across asset classes; managed services, including consolidation of client portfolio data, review and reconciliation of input data and results, and customized reporting; and HedgePlatform to measure, evaluate, and monitor the risk of hedge fund investments. The ESG and Climate segment provides products and services that help institutional investors understand how ESG impacts the long-term risk and return of their portfolio and individual security-level investments; and data, ratings, research, and tools to help investors navigate increasing regulation. The All Other Private Assets segment includes real estate and infrastructure data, benchmarks, return-analytics, climate assessments and market insights; business intelligence to real estate owners, managers, developers, and brokers; and offers investment decision support tools for private capital. The Private Capital Solutions segment offers tools to help private asset investors across mission-critical workflows, such as sourcing terms and conditions, evaluating operating performance, managing risk and other activities supporting private capital investing. MSCI Inc. was incorporated in 1998 and is headquartered in New York, New York.